American Century Companies Inc. Raises Stake in SI-BONE, Inc. (NASDAQ:SIBN)

American Century Companies Inc. increased its stake in SI-BONE, Inc. (NASDAQ:SIBN) by 22.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,986,476 shares of the company’s stock after purchasing an additional 368,637 shares during the quarter. American Century Companies Inc. owned 4.82% of SI-BONE worth $25,685,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Pier Capital LLC increased its holdings in SI-BONE by 80.7% in the second quarter. Pier Capital LLC now owns 377,001 shares of the company’s stock valued at $4,875,000 after buying an additional 168,417 shares in the last quarter. ClariVest Asset Management LLC increased its stake in SI-BONE by 20.7% in the 2nd quarter. ClariVest Asset Management LLC now owns 59,958 shares of the company’s stock valued at $775,000 after purchasing an additional 10,274 shares in the last quarter. Arizona State Retirement System raised its holdings in SI-BONE by 9.0% during the second quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock worth $141,000 after purchasing an additional 903 shares during the last quarter. VELA Investment Management LLC boosted its position in SI-BONE by 46.7% during the second quarter. VELA Investment Management LLC now owns 112,088 shares of the company’s stock worth $1,449,000 after purchasing an additional 35,674 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in SI-BONE by 1.5% in the second quarter. Rhumbline Advisers now owns 59,419 shares of the company’s stock valued at $768,000 after purchasing an additional 852 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

Insider Activity

In related news, insider Anthony J. Recupero sold 2,087 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $14.17, for a total value of $29,572.79. Following the completion of the transaction, the insider now directly owns 236,717 shares in the company, valued at $3,354,279.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Anthony J. Recupero sold 2,087 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $14.17, for a total transaction of $29,572.79. Following the completion of the transaction, the insider now owns 236,717 shares of the company’s stock, valued at $3,354,279.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Laura Francis sold 9,967 shares of SI-BONE stock in a transaction on Friday, August 16th. The shares were sold at an average price of $13.84, for a total transaction of $137,943.28. Following the completion of the transaction, the chief executive officer now owns 492,923 shares in the company, valued at approximately $6,822,054.32. The disclosure for this sale can be found here. Insiders sold a total of 25,023 shares of company stock valued at $347,749 over the last quarter. Company insiders own 5.40% of the company’s stock.

SI-BONE Price Performance

SI-BONE stock opened at $15.68 on Thursday. The stock has a market capitalization of $646.09 million, a P/E ratio of -14.39 and a beta of 1.22. SI-BONE, Inc. has a 12-month low of $11.76 and a 12-month high of $23.12. The company has a debt-to-equity ratio of 0.22, a current ratio of 9.17 and a quick ratio of 8.12. The firm’s 50-day moving average is $15.38 and its two-hundred day moving average is $14.90.

SI-BONE (NASDAQ:SIBN) last announced its earnings results on Monday, August 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. The firm had revenue of $39.97 million for the quarter, compared to analyst estimates of $38.95 million. SI-BONE had a negative net margin of 27.10% and a negative return on equity of 24.27%. During the same quarter last year, the business earned ($0.30) earnings per share. Equities analysts predict that SI-BONE, Inc. will post -0.89 earnings per share for the current year.

Analysts Set New Price Targets

SIBN has been the topic of several recent research reports. Needham & Company LLC decreased their price objective on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Truist Financial reduced their price target on shares of SI-BONE from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Finally, Morgan Stanley dropped their price objective on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $23.00.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.